Literature DB >> 21685232

Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.

K L Munger1, L I Levin, E J O'Reilly, K I Falk, A Ascherio.   

Abstract

BACKGROUND: Elevated Epstein-Barr virus (EBV) antibody titers are risk factors for multiple sclerosis (MS), but the strength and consistency of this association are not well characterized.
OBJECTIVES: The objectives of this study were to determine whether this association is confounded by vitamin D or modified by gender or race, and the usefulness of EBV nuclear antigen (EBNA) antibodies as a marker for MS.
METHODS: We conducted a prospective study among US military personnel. Antibody titers against EBV antigens were measured in serum samples from 222 individuals who developed MS and 444 age, sex, and race/ethnicity matched controls. Conditional logistic regression was used to estimate relative risks.
RESULTS: MS risk increased with increasing titers of anti-EBNA complex (p < 10(-9)) and anti-EBNA-1 (p = 5.8 × 10(-9)) titers. MS risk was 36-fold higher among individuals with anti-EBNA complex IgG titers ≥320 than among those with titers <20 (95% confidence interval [CI] 9.6-136), and 8-fold higher among those with anti-EBNA-1 ≥320 than among those with anti-EBNA-1 <20 (95% CI 2.6-23). These associations were consistent across gender and race/ethnicity groups and independent from 25-hydroxyvitamin D levels. Areas under the receiver operating characteristic (ROC) curves were 0.67 for EBNA complex and 0.65 for EBNA-1.
CONCLUSIONS: Serum titers of pre-onset anti-EBNA antibodies are strong, robust markers of MS risk and could be useful in an MS risk score.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21685232      PMCID: PMC3179777          DOI: 10.1177/1352458511408991

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  34 in total

Review 1.  The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance.

Authors:  Mark V Rubertone; John F Brundage
Journal:  Am J Public Health       Date:  2002-12       Impact factor: 9.308

2.  Epstein-Barr virus and multiple sclerosis.

Authors:  A Ascherio; M Munch
Journal:  Epidemiology       Date:  2000-03       Impact factor: 4.822

3.  Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells.

Authors:  Trygve Holmøy; Frode Vartdal
Journal:  J Neurovirol       Date:  2004-02       Impact factor: 2.643

4.  A functional and structural basis for TCR cross-reactivity in multiple sclerosis.

Authors:  Heather L E Lang; Helle Jacobsen; Shinji Ikemizu; Christina Andersson; Karl Harlos; Lars Madsen; Peter Hjorth; Leif Sondergaard; Arne Svejgaard; Kai Wucherpfennig; David I Stuart; John I Bell; E Yvonne Jones; Lars Fugger
Journal:  Nat Immunol       Date:  2002-09-03       Impact factor: 25.606

5.  An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis.

Authors:  Adam E Handel; Alexander J Williamson; Giulio Disanto; Lahiru Handunnetthi; Gavin Giovannoni; Sreeram V Ramagopalan
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

6.  Epstein-Barr virus in pediatric multiple sclerosis.

Authors:  Suad Alotaibi; Julia Kennedy; Raymond Tellier; Derek Stephens; Brenda Banwell
Journal:  JAMA       Date:  2004-04-21       Impact factor: 56.272

Review 7.  Genetics of multiple sclerosis.

Authors:  David A Dyment; George C Ebers; A Dessa Sadovnick
Journal:  Lancet Neurol       Date:  2004-02       Impact factor: 44.182

8.  1,25-dihydroxyvitamin D3 receptors in human leukocytes.

Authors:  D M Provvedini; C D Tsoukas; L J Deftos; S C Manolagas
Journal:  Science       Date:  1983-09-16       Impact factor: 47.728

9.  An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study.

Authors:  P Sundström; P Juto; G Wadell; G Hallmans; A Svenningsson; L Nyström; J Dillner; L Forsgren
Journal:  Neurology       Date:  2004-06-22       Impact factor: 9.910

10.  Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis.

Authors:  P Höllsberg; H J Hansen; S Haahr
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

View more
  56 in total

1.  Epstein-barr virus and multiple sclerosis risk in the finnish maternity cohort.

Authors:  Kassandra L Munger; Kira Hongell; Marianna Cortese; Julia Åivo; Merja Soilu-Hänninen; Heljä-Marja Surcel; Alberto Ascherio
Journal:  Ann Neurol       Date:  2019-07-03       Impact factor: 10.422

2.  Serum IgA to Epstein-Barr virus early antigen-diffuse identifies Hodgkin's lymphoma.

Authors:  Shane C McAllister; Duane Shedd; Nancy E Mueller; Ellen T Chang; George Miller; Sumita Bhaduri-McIntosh
Journal:  J Med Virol       Date:  2013-09-30       Impact factor: 2.327

Review 3.  Progress, prospects, and problems in Epstein-Barr virus vaccine development.

Authors:  Henry H Balfour
Journal:  Curr Opin Virol       Date:  2014-03-15       Impact factor: 7.090

4.  Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: inference for multiple sclerosis.

Authors:  Giuseppe Mameli; Luciana Poddighe; Alessandra Mei; Elena Uleri; Stefano Sotgiu; Caterina Serra; Roberto Manetti; Antonina Dolei
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

Review 5.  Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.

Authors:  Klemens Ruprecht; Brigitte Wildemann; Sven Jarius
Journal:  J Neurol       Date:  2017-11-02       Impact factor: 4.849

6.  Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.

Authors:  Katarina Tengvall; Jesse Huang; Cecilia Hellström; Patrick Kammer; Martin Biström; Burcu Ayoglu; Izaura Lima Bomfim; Pernilla Stridh; Julia Butt; Nicole Brenner; Angelika Michel; Karin Lundberg; Leonid Padyukov; Ingrid E Lundberg; Elisabet Svenungsson; Ingemar Ernberg; Sigurgeir Olafsson; Alexander T Dilthey; Jan Hillert; Lars Alfredsson; Peter Sundström; Peter Nilsson; Tim Waterboer; Tomas Olsson; Ingrid Kockum
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-02       Impact factor: 11.205

7.  Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Authors:  Charles Pierrot-Deseilligny; Jean-Claude Souberbielle
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

Review 8.  Epidemiology of Major Neurodegenerative Diseases in Women: Contribution of the Nurses' Health Study.

Authors:  Kaitlin A Hagan; Kassandra L Munger; Alberto Ascherio; Francine Grodstein
Journal:  Am J Public Health       Date:  2016-07-26       Impact factor: 9.308

Review 9.  The initiation and prevention of multiple sclerosis.

Authors:  Alberto Ascherio; Kassandra L Munger; Jan D Lünemann
Journal:  Nat Rev Neurol       Date:  2012-10-09       Impact factor: 42.937

10.  Serum concentration of immunoglobulin G-type antibodies against the whole Epstein-Barr nuclear antigen 1 and its aa35-58 or aa398-404 fragments in the sera of patients with systemic lupus erythematosus and multiple sclerosis.

Authors:  D Csuka; D Simon; R Hóbor; K Uray; Z Prohászka; Z Bánlaki; P K Jani; Á Szilágyi; F Hudecz; K Rajczy; G Beke; A Boros Major; A Tordai; Z Illés; T Berki; L Czirják; G Füst
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.